In its investor presentation, Laurus Labs said that they are well on track to deliver healthy operational growth for financial year 2026.

The final trading day of the week promises to be full of action with regards to quarterly results, with over 50 companies ...

Laurus Labs latest update leaves the fair value estimate at roughly ₹821.93 per share with a steady discount rate of 12.76%, underscoring that the market narrative is shifting more on expectations ...

Laurus Labs shares tanked 3 per cent in Friday's trade, despite a strong set of March quarter results, led by strong traction in the Formulation segment. This was the second consecutive quarter of ...

India, Jan. 23 -- This mid-cap Pharma stock, engaged in developing and manufacturing APIs, formulations, and biotech products ...

An analyst from Master Capital Services said that Bank of India has taken strong support at its long-term horizontal support ...

Despite the broader market strength, Laurus Labs appears to be under pressure as CITI has maintained its ‘Sell’ rating with a target price of Rs 590. With the stock currently around Rs 1,030, the ...

SUNNYVALE, Calif., May 30, 2024 /PRNewswire/ - Willow Biosciences Inc. ("Willow") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of ...

The strategic alliance includes an initial seven high-value advanced intermediates and active pharmaceutical ingredients, including Willow's corticosteroid programs The agreement with Laurus is the ...